Cipla runs into FDA concerns for plant in India, as well as one it will buy in U.S.

While many of India's other large drugmakers have run afoul of the FDA for plant problems, Cipla has mostly avoided such entanglements. But suddenly the company is facing some FDA issues at two plants, one in India, and one in the U.S. that it intends to buy to gain a foothold in U.S. manufacturing. Citing a Form 483, the Economic Times said the FDA tagged Cipla's Indore plant for failing to fully investigate problems with an asthma inhalant that it had to recall from the U.S. last spring. Additionally, the Hauppauge, NY, plant that Cipla will get as part of its $550 million deal to buy U.S.-based InvaGen Pharmaceuticals, received a Form 483 several months ahead of that announcement. Story | More from FiercePharmaManufacturing

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.